Resources
Intelligence → Decision → Tool → ServiceArticles
- 01CD155 与 DNAM-1 交叉竞争：为什么你的 TIGIT 筛选必须加这个对照Articles
- 02Experimental Design: CD16a 158V vs 158F Side-by-Side ComparisonArticles
- 03How to Select the Right CD16a (FcγRIIIa) Variant for FcγR Binding StudiesArticles
- 04CD47 / SIRPα Blocking Assay Design: Avoiding the Pitfalls That Invalidate Your DataArticles
- 05Choosing CD3 Protein Formats for T-Cell Engager DevelopmentArticles
- 06CHO vs HEK293 for Early BsAb ExpressionArticles
- 07How to Design a DLL3 × CD3 Functional Screening WorkflowArticles
- 08How to Validate Dual Binding for a Bispecific AntibodyArticles
- 09Human vs Cynomolgus Antigen SelectionArticles
- 10How to Design an FcRn SPR Assay for pH-Dependent Antibody Half-Life EvaluationArticles
- 11Step-by-Step: FcRn SPR Protocol with pH 6.0 / 7.4 Dual-Buffer SwitchArticles
- 12FcRn 半衰期工程的突变策略：YTE、LS 与 N434A 怎么选Articles
- 13IL-15 for NK Cell Expansion: Concentrations, Combinations, and Common FailuresArticles
- 14IL-15 vs IL-15/IL-15Rα Complex：什么时候复合物值得多花钱Articles
- 15IL-21 在 NK 扩增中的角色：何时加、加多少、为什么Articles
- 16PD-1 × VEGF-A Target Pair Landscape — What's Happening and Why It MattersArticles
- 17PD-L1 × VEGF-A Target Pair Landscape — Axis Validated, Format UnapprovedArticles
- 18DLL3 × CD3 Target Pair Landscape — The TCE Benchmark PairArticles
- 19EGFR × LGR5 Target Pair Landscape — An Emerging Pair With a Real Reagent GapArticles
- 20EGFR × MET Target Pair Landscape — Approved Reference, Multi-Generational PipelineArticles
- 21PD-1 / PD-L1 通路研究基础：从机制到实验设计的关键认知Articles
- 22TIGIT / CD155 Matched Pair: Workflow and Optimization for BLI and SPRArticles
Hubs
- 01B7-H3 Hub — 4Ig 跨膜靶点的抗体发现与验证Hubs
- 02CD16a Hub — FcγRIIIa Variants & ADCC EvaluationHubs
- 03CD47 / SIRPα Hub — Macrophage Checkpoint Discovery ToolsHubs
- 04FcRn Hub — Antibody Half-Life & Fc EngineeringHubs
- 05IL-15 Hub — NK Expansion & Cell Therapy CytokinesHubs
- 06TIGIT / CD155 Hub — Matched Pair for Checkpoint ScreeningHubs